Oxycodone transdermal - Phosphagenics

Drug Profile

Oxycodone transdermal - Phosphagenics

Alternative Names: Sustained-release oxycodone patch - Phosphagenics; TPM/O patch; TPM/oxycodone patch - Phosphagenics; TPM®/Oxycodone patch

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Phosphagenics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • Phase I Pain
  • No development reported Neuropathic pain

Most Recent Events

  • 10 Nov 2016 Phosphagenics extends the term of licence option granted to Terumo under May 2016 agreement
  • 16 Feb 2016 No recent reports on development identified - Preclinical for Neuropathic pain in Australia (Topical)
  • 29 Jan 2016 Efficacy data from a phase IIa trial in postherpetic pain, which failed to meet the primary endpoint, released by Phosphagenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top